Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Statistical methods for assessment of added usefulness of new biomarkers.

Pencina MJ, D'Agostino RB, Vasan RS.

Clin Chem Lab Med. 2010 Dec;48(12):1703-11. doi: 10.1515/CCLM.2010.340. Epub 2010 Aug 18. Review.

2.

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Pencina MJ, D'Agostino RB Sr, Steyerberg EW.

Stat Med. 2011 Jan 15;30(1):11-21. doi: 10.1002/sim.4085. Epub 2010 Nov 5.

3.

Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives.

Steyerberg EW, Vedder MM, Leening MJ, Postmus D, D'Agostino RB Sr, Van Calster B, Pencina MJ.

Biom J. 2015 Jul;57(4):556-70. doi: 10.1002/bimj.201300260. Epub 2014 Jul 18.

PMID:
25042996
4.

Interpreting incremental value of markers added to risk prediction models.

Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P.

Am J Epidemiol. 2012 Sep 15;176(6):473-81. Epub 2012 Aug 8.

5.

Assessing the performance of prediction models: a framework for traditional and novel measures.

Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW.

Epidemiology. 2010 Jan;21(1):128-38. doi: 10.1097/EDE.0b013e3181c30fb2.

6.

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS.

Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12.

PMID:
17569110
7.

Assessing the incremental predictive performance of novel biomarkers over standard predictors.

Xanthakis V, Sullivan LM, Vasan RS, Benjamin EJ, Massaro JM, D'Agostino RB Sr, Pencina MJ.

Stat Med. 2014 Jul 10;33(15):2577-84. doi: 10.1002/sim.6165. Epub 2014 Apr 9.

8.

Improvement in stroke risk prediction: role of C-reactive protein and lipoprotein-associated phospholipase A2 in the women's health initiative.

Wassertheil-Smoller S, McGinn A, Allison M, Ca T, Curb D, Eaton C, Hendrix S, Kaplan R, Ko M, Martin LW, Xue X.

Int J Stroke. 2014 Oct;9(7):902-9. doi: 10.1111/j.1747-4949.2012.00860.x. Epub 2012 Oct 23.

9.

[Discriminative ability, reclassification and net benefit: the predictive value of biomarkers].

Steyerberg EW, Pencina MJ, Van Calster B.

Ned Tijdschr Geneeskd. 2012;156(41):A5029. Review. Dutch.

PMID:
23062255
10.

The potential of genes and other markers to inform about risk.

Pepe MS, Gu JW, Morris DE.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):655-65. doi: 10.1158/1055-9965.EPI-09-0510. Epub 2010 Feb 16.

11.

Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide.

Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW.

Ann Intern Med. 2014 Jan 21;160(2):122-31. Review.

PMID:
24592497
12.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

13.

Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers.

Kerr KF, Meisner A, Thiessen-Philbrook H, Coca SG, Parikh CR.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1488-96. doi: 10.2215/CJN.10351013. Epub 2014 May 22. Review.

14.

New metrics for assessing diagnostic potential of candidate biomarkers.

Pickering JW, Endre ZH.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1355-64. doi: 10.2215/CJN.09590911. Epub 2012 Jun 7. Erratum in: Clin J Am Soc Nephrol. 2012 Oct;7(10):1740.

15.

The Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement Even with Independent Test Data Sets.

Pepe MS, Fan J, Feng Z, Gerds T, Hilden J.

Stat Biosci. 2015 Oct 1;7(2):282-295. Epub 2014 Aug 23.

16.

Clinically relevant measures of fit? A note of caution.

Cook NR.

Am J Epidemiol. 2012 Sep 15;176(6):488-91. Epub 2012 Aug 8.

17.

Net reclassification indices for evaluating risk prediction instruments: a critical review.

Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS.

Epidemiology. 2014 Jan;25(1):114-21. doi: 10.1097/EDE.0000000000000018. Review.

18.

Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study.

Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A; GREAT-Network.

Int J Cardiol. 2013 Oct 3;168(3):2186-94. doi: 10.1016/j.ijcard.2013.01.228. Epub 2013 Mar 26.

PMID:
23538053
19.

Net risk reclassification p values: valid or misleading?

Pepe MS, Janes H, Li CI.

J Natl Cancer Inst. 2014 Apr;106(4):dju041. doi: 10.1093/jnci/dju041. Epub 2014 Mar 28.

20.

Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models.

Pencina MJ, D'Agostino RB Sr, Demler OV.

Stat Med. 2012 Jan 30;31(2):101-13. doi: 10.1002/sim.4348. Epub 2011 Dec 7.

Supplemental Content

Support Center